ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.74 No.6 November 2026

A case of drug-induced liver injury caused by oral voriconazole in a patient with short bowel syndrome and 30 cm of residual small intestine

Kenta Nakamoto1, 2), Hidemasa Akazawa1, 2), Shinnosuke Fukushima1, 3), Kohei Oguni1, 2), Yohei Manabe4), Kyoko Yokota5) and Hideharu Hagiya1, 6)

1)Department of Infectious Diseases, Okayama University Hospital, 2-5-1 Shikata, Kita-ku, Okayama, Japan
2)Department of General Medicine, Okayama University Hospital
3)Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
4)Department of Pharmacy, Okayama University Hospital
5)Center of Infectious Disease Education, Kagawa University Hospital
6)Research Center for Intestinal Health Science, Okayama University

Abstract

A man in his sixties with short bowel syndrome (SBS), in whom a residual 30 cm of the small intestine from the Ligament of Treitz remained following bowel resection for non-occlusive mesenteric ischemia, was transferred to our hospital for management of refractory liver dysfunction. The patient had previously undergone ascending aorta–to–abdominal aorta bypass for aortitis syndrome. He was receiving treatment for persistent Candida parapsilosis candidemia with intravenous micafungin and voriconazole (VRCZ), when he developed laboratory evidence of liver injury. Intravenous VRCZ was switched to oral therapy despite concerns about limited drug absorption. However, in fact, the serum concentrations rose significantly, leading to worsening the VRCZ-induced liver injury. Following dose reduction guided by therapeutic drug monitoring (TDM), the blood cultures turned positive once the serum levels fell within the standard therapeutic range, rendering VRCZ clinically non-viable. This case serves to highlight the fact that even with an extremely short remnant intestine of 30 cm, a sufficient amount of VRCZ can be absorbed into the blood, possibly owing to intestinal adaptation, further highlighting the risk of an unexpectedly high concentration caused by individual differences in metabolic capacity and drug interactions.

Key word

voriconazole, short bowel syndrome, hepatotoxicity, therapeutic drug monitoring

Received

March 3, 2026

Accepted

July 9, 2026

Jpn. J. Chemother. 74 (6): 785-791, 2026